HRP20240402T1 - Poboljšane medicinske aerosolne formulacije - Google Patents

Poboljšane medicinske aerosolne formulacije Download PDF

Info

Publication number
HRP20240402T1
HRP20240402T1 HRP20240402TT HRP20240402T HRP20240402T1 HR P20240402 T1 HRP20240402 T1 HR P20240402T1 HR P20240402T T HRP20240402T T HR P20240402TT HR P20240402 T HRP20240402 T HR P20240402T HR P20240402 T1 HRP20240402 T1 HR P20240402T1
Authority
HR
Croatia
Prior art keywords
weight
formulation
use according
amount
propellant gas
Prior art date
Application number
HRP20240402TT
Other languages
English (en)
Croatian (hr)
Inventor
Rudi Mueller-Walz
Lise-Marie Fueg
Original Assignee
Jagotec Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41462450&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20240402(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jagotec Ag filed Critical Jagotec Ag
Publication of HRP20240402T1 publication Critical patent/HRP20240402T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20240402TT 2009-10-16 2010-10-15 Poboljšane medicinske aerosolne formulacije HRP20240402T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0918149.6A GB0918149D0 (en) 2009-10-16 2009-10-16 Improved medicinal aerosol formulation
EP14199881.5A EP2881108B1 (en) 2009-10-16 2010-10-15 Improved medicinal aerosol formulations

Publications (1)

Publication Number Publication Date
HRP20240402T1 true HRP20240402T1 (hr) 2024-06-07

Family

ID=41462450

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20240402TT HRP20240402T1 (hr) 2009-10-16 2010-10-15 Poboljšane medicinske aerosolne formulacije
HRP20150174TT HRP20150174T1 (hr) 2009-10-16 2010-10-15 Poboljšane medicinske aerosolne formulacije

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20150174TT HRP20150174T1 (hr) 2009-10-16 2010-10-15 Poboljšane medicinske aerosolne formulacije

Country Status (26)

Country Link
US (3) US20120282189A1 (enExample)
EP (3) EP2488158B1 (enExample)
JP (6) JP2013507430A (enExample)
CN (1) CN102665675B (enExample)
AU (1) AU2010305698C9 (enExample)
BR (1) BR112012008983A2 (enExample)
CA (1) CA2776359C (enExample)
CL (1) CL2012000947A1 (enExample)
CY (1) CY1116109T1 (enExample)
DK (2) DK2881108T3 (enExample)
ES (2) ES2533372T3 (enExample)
FI (1) FI2881108T3 (enExample)
GB (1) GB0918149D0 (enExample)
HR (2) HRP20240402T1 (enExample)
HU (1) HUE065583T2 (enExample)
IL (1) IL219161B (enExample)
LT (1) LT2881108T (enExample)
MX (1) MX2012004337A (enExample)
NZ (1) NZ599901A (enExample)
PL (2) PL2488158T3 (enExample)
PT (2) PT2488158E (enExample)
RS (2) RS65391B1 (enExample)
SI (2) SI2488158T1 (enExample)
SM (2) SMT202400119T1 (enExample)
WO (1) WO2011045432A1 (enExample)
ZA (1) ZA201202452B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE50211045D1 (de) * 2001-03-30 2007-11-22 Jagotec Ag Medizinische aerosolformulierungen
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0918149D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
TWI495466B (zh) * 2010-09-23 2015-08-11 Intech Biopharm Ltd 用於氣喘之吸入性複方組合物
GB201515310D0 (en) * 2015-08-27 2015-10-14 Jagotec Ag Pharmaceutical composition

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2503962A1 (de) 1975-01-31 1976-08-05 Thomae Gmbh Dr K Spruehbare mittel in suspensionsform zur anwendung auf der haut
FR2420972A1 (fr) 1978-03-31 1979-10-26 Roussel Uclaf Application du peroxyde de thenoyle a titre de medicament
JPS5529524A (en) 1978-08-21 1980-03-01 Toyo Aerosol Kogyo Kk Powdery aerosol composition
DE2914181C2 (de) 1979-04-07 1982-06-16 Kernforschungsanlage Jülich GmbH, 5170 Jülich Verfahren und Vorrichtung zum Trocknen temperaturempfindlicher Güter der Pharma- und Nahrungsmittelindustrie
JPS6135815A (ja) 1984-07-28 1986-02-20 Sanshin Seisakusho:Kk 上部集液式加圧ろ過機に於ける機体内液の脱液方法及び同装置
FR2666962B1 (fr) 1990-09-26 1996-06-14 Oreal Composition antifongique sous forme de spray sec.
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
SE9101090D0 (sv) 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
DE69218455T2 (de) * 1991-12-18 1997-10-23 Minnesota Mining And Mfg. Co., Saint Paul, Minn. Aerosolzusammensetzungen für arzneimittelsuspensionen
DE4321288A1 (de) 1993-06-26 1995-01-05 Solvay Fluor & Derivate Zusammensetzungen mit chlorfreien, gegebenenfalls wasserstoffhaltigen Fluorkohlenwasserstoffen
US6596260B1 (en) 1993-08-27 2003-07-22 Novartis Corporation Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
ATE233544T1 (de) 1993-12-02 2003-03-15 Abbott Lab Aerosole als darreichungsform mit cfc-freiem treibmittel
AP979A (en) 1995-04-14 2001-06-28 Glaxo Wellcome Inc Metered dose imhaler for salmeterol.
JP3707107B2 (ja) 1995-09-18 2005-10-19 鈴木油脂工業株式会社 薬剤分散液及びその製造方法
US6054488A (en) 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
US6361938B1 (en) 1996-11-08 2002-03-26 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
ATE290368T1 (de) 1997-01-30 2005-03-15 Alltracel Dev Services Ltd Blutstillende aerosol-zubereitung
NZ337065A (en) 1997-02-05 2001-02-23 Jago Pharma Ag Medical aerosol formulations containing carbon dioxide, a hydrofluoroalkane, a cosolvent and a beta-mimetic / corticoid / anticholinergic / spasmolytic / analgesic agent
US6086376A (en) 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
US6451285B2 (en) 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
DE59911149D1 (de) 1998-07-24 2004-12-30 Jago Res Ag Muttenz Medizinische aerosolformulierungen
AU749697B2 (en) 1998-08-04 2002-07-04 Jagotec Ag Medicinal aerosol formulations
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
ATE382386T1 (de) 1998-11-13 2008-01-15 Jagotec Ag Multidosis-trockenpulverinhalator mit pulverreservoir
US7074388B2 (en) * 1998-12-10 2006-07-11 Kos Life Science, Inc. Water stabilized medicinal aerosol formulation
US6926911B1 (en) 1998-12-22 2005-08-09 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
WO2000047203A1 (en) 1999-02-12 2000-08-17 Mqs, Inc. Formulation and system for intra-oral delivery of pharmaceutical agents
GB9903759D0 (en) 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9904919D0 (en) 1999-03-03 1999-04-28 Novartis Ag Organic compounds
GB0012260D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
GB0012261D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
BR0015884A (pt) 2000-05-22 2003-07-08 Chiesi Farma Spa Formulações de soluções farmacêuticas estáveis para inaladores de dose medida pressurizados
AU2001247123A1 (en) * 2000-07-19 2002-02-05 Aeropharm Technology, Inc. A medicinal aerosol formulation
WO2002011711A2 (en) 2000-08-04 2002-02-14 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
JP5021149B2 (ja) 2000-10-09 2012-09-05 スリーエム イノベイティブ プロパティズ カンパニー 医療用エアロゾル調合物
DE50211045D1 (de) * 2001-03-30 2007-11-22 Jagotec Ag Medizinische aerosolformulierungen
US6455028B1 (en) 2001-04-23 2002-09-24 Pharmascience Ipratropium formulation for pulmonary inhalation
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
AR036358A1 (es) 2001-08-28 2004-09-01 Schering Corp Un inhalador de dosis medidas que contiene una formulacion de suspension en aerosol para inhalacion, un proceso para la produccion de la formulacion, el producto y el uso de una formulacion para la manufactura de un medicamento de asma
GB0201400D0 (en) 2002-01-22 2002-03-13 Glaxo Group Ltd Novel apparatus and process
HUE044926T2 (hu) 2002-03-01 2019-11-28 Chiesi Farm Spa Szuperfinom formoterolkészítmény
GB0207899D0 (en) 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and cielesonide aerosol formulations
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
EP2319583A1 (en) * 2002-08-29 2011-05-11 Cipla Ltd. Pharmaceutical products and compositions comprising salmeterol, budesonide and ipratropium
US20060193610A1 (en) 2003-07-12 2006-08-31 Jong-Hun Han Aromatic emitting apparatus for using cigarjack
CA2539051C (en) 2003-09-19 2014-08-12 Penwest Pharmaceuticals Co. Delayed release dosage forms
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
CA2581999C (en) * 2004-10-12 2013-04-23 Generics (Uk) Limited Preparation of suspension aerosol formulations
GB0918150D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved formulations
GB0918149D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
JP2015036045A (ja) * 2013-08-12 2015-02-23 株式会社泉技研 骨質改善のための超音波音響システム及び超音波音響機器の作動方法

Also Published As

Publication number Publication date
AU2010305698B2 (en) 2012-12-20
JP2023026517A (ja) 2023-02-24
JP2025148616A (ja) 2025-10-07
PL2881108T3 (pl) 2024-06-17
EP2488158B1 (en) 2014-12-24
CY1116109T1 (el) 2017-02-08
HK1173077A1 (en) 2013-05-10
EP4327807A3 (en) 2024-04-24
CL2012000947A1 (es) 2012-12-14
JP2013507430A (ja) 2013-03-04
JP2015129162A (ja) 2015-07-16
EP2488158A1 (en) 2012-08-22
EP2881108B1 (en) 2023-12-27
PT2881108T (pt) 2024-03-13
AU2010305698C9 (en) 2014-04-17
HK1211207A1 (en) 2016-05-20
WO2011045432A1 (en) 2011-04-21
LT2881108T (lt) 2024-04-10
BR112012008983A2 (pt) 2016-04-05
ES2973882T3 (es) 2024-06-24
JP7203701B2 (ja) 2023-01-13
SI2488158T1 (sl) 2015-04-30
EP4327807A2 (en) 2024-02-28
SI2881108T1 (sl) 2024-04-30
HUE065583T2 (hu) 2024-06-28
US20140314684A1 (en) 2014-10-23
CA2776359C (en) 2015-12-08
PT2488158E (pt) 2015-03-16
FI2881108T3 (fi) 2024-03-13
US20170189423A1 (en) 2017-07-06
HRP20150174T1 (hr) 2015-05-22
ES2533372T3 (es) 2015-04-09
US20120282189A1 (en) 2012-11-08
JP2017057223A (ja) 2017-03-23
US10471077B2 (en) 2019-11-12
SMT201500052B (it) 2015-05-05
DK2488158T3 (en) 2015-03-23
JP6568511B2 (ja) 2019-08-28
RS53883B1 (sr) 2015-08-31
ZA201202452B (en) 2013-09-25
PL2488158T3 (pl) 2015-06-30
EP2881108A1 (en) 2015-06-10
AU2010305698C1 (en) 2013-07-25
IL219161B (en) 2019-12-31
IL219161A0 (en) 2012-06-28
CN102665675A (zh) 2012-09-12
SMT202400119T1 (it) 2024-05-14
DK2881108T3 (da) 2024-03-11
MX2012004337A (es) 2012-08-31
CA2776359A1 (en) 2011-04-21
GB0918149D0 (en) 2009-12-02
AU2010305698A1 (en) 2012-04-26
RS65391B1 (sr) 2024-04-30
CN102665675B (zh) 2014-03-19
JP2019182878A (ja) 2019-10-24
NZ599901A (en) 2013-08-30

Similar Documents

Publication Publication Date Title
JP2010132695A5 (enExample)
IN2015DN02328A (enExample)
HRP20150452T1 (hr) Ureä�aj za sprej za nos
HRP20240402T1 (hr) Poboljšane medicinske aerosolne formulacije
ECSP088653A (es) Formulacion farmacéutica para aerosoles con dos o más principios activos y al menos una sustancia tensoactiva
AR049142A1 (es) Composiciones para recubrimientos de azucar,composiciones recubiertas y metodos para la fabricacion de los mismos
MEP18208A (en) Immune response modifier foam formulations
EP2571486A4 (en) DRY POWDER INHALATION COMPOSITION
CO6680640A2 (es) Uso de aglutinantes para fabircar formulaciones estables al almacenamiento
AR089337A1 (es) Composiciones para el cuidado oral
AR054609A1 (es) Composiciones similares a batido que contienen agente de solidificacion y metodos para prepararlas y usarlas
BR112015027017A2 (pt) composições farmacêuticas inaláveis e dispositivos inaladores que contêm as mesmas
UY30241A1 (es) Aerosoles dosificadores para la administracion de preparaciones farmaceuticas
EA201270745A1 (ru) Улучшенный стабильный водный состав (e)-4-карбоксистирил-4-хлорбензилсульфона
WO2011093818A3 (en) Pharmaceutical compositions comprising salmeterol and fluticasone
WO2011093815A3 (en) Pharmaceutical compositions comprising formoterol and mometasone
WO2011101734A3 (en) Taste-masked powder for suspension compositions of methylprednisolone
MX345888B (es) Emulsion aceite en agua de mometasona y propilenglicol.
WO2011139249A3 (en) Pharmaceutical composition comprising cefdinir
CO7240380A2 (es) Composiciones líquidas orales pediátricas que contienen nepadutant
AR070974A1 (es) Formulacion en suspension para adsorbentes de carbono
WO2011093811A3 (en) Pharmaceutical preparations comprising formoterol and fluticasone
WO2011093812A3 (en) Pharmaceutical formulation comprising tiotropium and budesonide in dry powder form
BR112015014180A2 (pt) composições de gel
WO2011093814A3 (en) A pharmaceutical combination comprising formoterol and ciclesonide